glp1 tirzepatide GLP-1 use tripled among non-diabetics, reaching $5.8B in 2022 Tirzepatide for Medical Weight Loss
Description
Consult Pharmacy Planet for personalized expert guidance and start your weight loss journey today.
People taking GLP-1s had reduced risk for atrial fibrillation, regardless of whether they lost weight or how much they lost, according to findings presented at Heart Rhythm 2026
Let's take a look why this is happening and how to manage it.
We conducted a retrospective multicenter national study examining the risk of gastric and esophageal cancer in patients with type 2 diabetes who were receiving glucagon-like peptide receptor agonists
Some patients report theyve lost interest in drinking, are put off by the smell and taste of alcohol or experience more severe hangover symptoms.
